메뉴 건너뛰기




Volumn 24, Issue 9, 2018, Pages 1695-1705

Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis

Author keywords

adverse event; colitis; diarrhea; endoscopy; histology; immune checkpoint inhibitor; immunotherapy

Indexed keywords

CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNE CHECKPOINT INHIBITOR; IMMUNOMODULATING AGENT; INFLIXIMAB; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; TICILIMUMAB; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

EID: 85054005535     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1093/ibd/izy104     Document Type: Article
Times cited : (188)

References (19)
  • 1
    • 84928062583 scopus 로고    scopus 로고
    • Immune checkpoint blockade: A common denominator approach to cancer therapy
    • Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell. 2015;27:450-61.
    • (2015) Cancer Cell. , vol.27 , pp. 450-461
    • Topalian, S.L.1    Drake, C.G.2    Pardoll, D.M.3
  • 2
    • 84858766182 scopus 로고    scopus 로고
    • The blockade of immune checkpoints in cancer immunotherapy
    • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-64.
    • (2012) Nat Rev Cancer. , vol.12 , pp. 252-264
    • Pardoll, D.M.1
  • 3
    • 84255197842 scopus 로고    scopus 로고
    • Cancer immunotherapy comes of age
    • Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480-9.
    • (2011) Nature. , vol.480 , pp. 480-489
    • Mellman, I.1    Coukos, G.2    Dranoff, G.3
  • 4
    • 84929481482 scopus 로고    scopus 로고
    • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
    • Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006-17.
    • (2015) N Engl J Med. , vol.372 , pp. 2006-2017
    • Postow, M.A.1    Chesney, J.2    Pavlick, A.C.3
  • 5
    • 84924901863 scopus 로고    scopus 로고
    • Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (checkmate 063): A phase 2, single-arm trial
    • Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (checkmate 063): A phase 2, single-arm trial. Lancet Oncol. 2015;16:257-65.
    • (2015) Lancet Oncol. , vol.16 , pp. 257-265
    • Rizvi, N.A.1    Mazieres, J.2    Planchard, D.3
  • 6
    • 84862859820 scopus 로고    scopus 로고
    • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    • Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-54.
    • (2012) N Engl J Med. , vol.366 , pp. 2443-2454
    • Topalian, S.L.1    Hodi, F.S.2    Brahmer, J.R.3
  • 7
    • 84864052441 scopus 로고    scopus 로고
    • Management of immune-related adverse events and kinetics of response with ipilimumab
    • Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691-7.
    • (2012) J Clin Oncol. , vol.30 , pp. 2691-2697
    • Weber, J.S.1    Kahler, K.C.2    Hauschild, A.3
  • 8
    • 84953309212 scopus 로고    scopus 로고
    • Immune-related adverse events with immune checkpoint blockade: A comprehensive review
    • Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: A comprehensive review. Eur J Cancer. 2016;54:139-48.
    • (2016) Eur J Cancer. , vol.54 , pp. 139-148
    • Michot, J.M.1    Bigenwald, C.2    Champiat, S.3
  • 9
    • 84969535050 scopus 로고    scopus 로고
    • Managing adverse events with immune checkpoint agents
    • Dadu R, Zobniw C, Diab A. Managing adverse events with immune checkpoint agents. Cancer J. 2016;22:121-9.
    • (2016) Cancer J. , vol.22 , pp. 121-129
    • Dadu, R.1    Zobniw, C.2    Diab, A.3
  • 10
    • 33744792341 scopus 로고    scopus 로고
    • Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
    • Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24:2283-2289.
    • (2006) J Clin Oncol. , vol.24 , pp. 2283-2289
    • Beck, K.E.1    Blansfield, J.A.2    Tran, K.Q.3
  • 11
    • 84975728236 scopus 로고    scopus 로고
    • Management of toxicities of immune checkpoint inhibitors
    • Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51-60.
    • (2016) Cancer Treat Rev. , vol.44 , pp. 51-60
    • Spain, L.1    Diem, S.2    Larkin, J.3
  • 12
    • 85012893091 scopus 로고    scopus 로고
    • Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
    • Bergqvist V, Hertervig E, Gedeon P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother. 2017;66:581-92.
    • (2017) Cancer Immunol Immunother. , vol.66 , pp. 581-592
    • Bergqvist, V.1    Hertervig, E.2    Gedeon, P.3
  • 13
    • 85034749402 scopus 로고    scopus 로고
    • Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group
    • Society for Immunotherapy of Cancer Toxicity Management Working Group
    • Puzanov I, Diab A, Abdallah K, et al. ; Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5:95.
    • (2017) J Immunother Cancer. , vol.5 , pp. 95
    • Puzanov, I.1    Diab, A.2    Abdallah, K.3
  • 14
    • 85015726665 scopus 로고    scopus 로고
    • Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis
    • Jain A, Lipson EJ, Sharfman WH, et al. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis. World J Gastroenterol. 2017;23:2023-8.
    • (2017) World J Gastroenterol. , vol.23 , pp. 2023-2028
    • Jain, A.1    Lipson, E.J.2    Sharfman, W.H.3
  • 15
    • 85015255948 scopus 로고    scopus 로고
    • Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies
    • Chen JH, Pezhouh MK, Lauwers GY, et al. Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am J Surg Pathol. 2017;41:643-54.
    • (2017) Am J Surg Pathol. , vol.41 , pp. 643-654
    • Chen, J.H.1    Pezhouh, M.K.2    Lauwers, G.Y.3
  • 16
    • 84963860995 scopus 로고    scopus 로고
    • Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis
    • Verschuren EC, van den Eertwegh AJ, Wonders J, et al. Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis. Clin Gastroenterol Hepatol. 2016;14:836-42.
    • (2016) Clin Gastroenterol Hepatol. , vol.14 , pp. 836-842
    • Verschuren, E.C.1    Van Den Eertwegh, A.J.2    Wonders, J.3
  • 17
    • 70350244517 scopus 로고    scopus 로고
    • Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab
    • Johnston RL, Lutzky J, Chodhry A, et al. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci. 2009;54:2538-40.
    • (2009) Dig Dis Sci. , vol.54 , pp. 2538-2540
    • Johnston, R.L.1    Lutzky, J.2    Chodhry, A.3
  • 18
    • 84940746759 scopus 로고    scopus 로고
    • Immune related adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis
    • Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211.
    • (2015) BMC Med. , vol.13 , pp. 211
    • Bertrand, A.1    Kostine, M.2    Barnetche, T.3
  • 19
    • 84899710302 scopus 로고    scopus 로고
    • Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient
    • Merrill SP, Reynolds P, Kalra A, et al. Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient. Ann Pharmacother. 2014;48:806-10.
    • (2014) Ann Pharmacother. , vol.48 , pp. 806-810
    • Merrill, S.P.1    Reynolds, P.2    Kalra, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.